PRP injections for erectile dysfunction: decode the P-shot protocol and evidence

PRP injected for erectile dysfunction is not one standardized “P-shot,” and the AUA guideline says intracavernosal platelet-rich plasma should be considered experimental. If a seller invokes FDA clearance for a preparation device, verify the exact 510(k) and intended use; a device clearance does not make the later injection procedure FDA approved for ED. Evaluate the exact preparation, injection protocol, patient population, comparator, endpoint, adverse-event plan, and responsible urology care.¹²³⁵

This article does not diagnose ED or select treatment. It shows how to turn a trademark-like sales phrase into a reviewable clinical and evidence record.

“PRP” begins as a process, not a fixed dose

PRP is prepared from a person’s blood. The collection tube, anticoagulant, centrifuge, spin settings, separation, final volume, platelet concentration, leukocyte and red-cell content, activation, sterility controls, time to injection, and number of sessions can all vary.

If a clinic cannot describe its protocol well enough to match it to a study, it cannot fairly borrow that study’s result.

Device clearance does not climb into procedure approval

FDA explains that a 510(k) clearance is a finding of substantial equivalence for the submitted device and intended use; changing intended use can require a new submission.⁵ If a clinic claims clearance for a centrifuge or preparation kit, open the exact record. That clearance does not establish that FDA approved a later intracavernosal injection for ED, that the device produces the same PRP as a cited trial, or that a branded protocol is effective.

Ask the clinic to identify:

• the device manufacturer, model, 510(k) number, and intended use;
• whether the kit and disposables match the cleared system;
• the exact preparation steps and any deviations;
• every additive or activating substance;
• the claim being made about the resulting injection; and
• the evidence for that exact product-process-procedure chain.

“FDA registered,” “FDA compliant,” and “uses an FDA-cleared kit” are not synonyms for “FDA-approved P-shot.” The approval-language guide explains those record types.

The randomized evidence does not tell one uniform story

One 2023 double-blind randomized trial enrolled 61 men with mild-to-moderate ED and compared two PRP injections one month apart with placebo. It reported no between-group difference in its primary clinically important response outcome one month after the second injection and no difference in the reported vascular parameters through follow-up.² That result belongs to that protocol, population, sample size, and endpoint.

An earlier double-blind randomized study reported favorable erectile-function findings under a different protocol.⁴ A 2026 meta-analysis of seven randomized trials found high heterogeneity and did not find consistent, clinically meaningful PRP-monotherapy improvement over placebo across its assessed time points; it called for larger standardized trials.³

The responsible summary is not “PRP works” or “PRP never works.” It is that protocols and findings vary, evidence certainty is limited, and a seller should disclose the exact trial match and uncertainty. A pooled average cannot repair weak blinding, selective reporting, small samples, incompatible preparations, or short follow-up.

Start with an ED evaluation, not an injection package

The AUA guideline frames ED evaluation around medical, sexual, and psychosocial history, physical examination, selective laboratory testing, cardiovascular context, shared decision-making, and established treatment options.¹ A regenerative-procedure consultation should not bypass that work.

Ask who:

• established the diagnosis and considered possible contributors;
• reviews medicines, substances, cardiovascular risk, endocrine factors, pelvic surgery or radiation, and mental-health context;
• explains established alternatives and the option of no procedure;
• coordinates with the person’s primary or specialty care; and
• owns follow-up if symptoms change or the procedure does not help.

A questionnaire can standardize a symptom report. It is not a diagnosis by itself, and a small score change is not automatically noticeable or durable.

Consent should name the uncertainty

The consent should state that the guideline considers the use experimental, describe the clinic’s protocol, identify known and uncertain risks, list alternatives, explain privacy around sexual-health records, and avoid a guaranteed response. It should separate common injection issues from less common or incompletely characterized complications and give a specific urgent-contact route.

Ask whether the clinic tracks every treated patient with a prespecified validated outcome, denominator, time point, missed follow-up, adverse event, and additional treatment. Testimonials and selected responders cannot answer those questions.

Price the experiment honestly

The quote should separate consultation, diagnostic workup, blood collection, preparation, injection, anesthesia, number of sessions, follow-up, validated outcome measurement, complication care, and any recommended adjunct. Ask whether unused sessions are refundable and what happens if the clinician advises stopping.

Do not finance multiple sessions on the assumption that more is proven better. A series is part of the protocol and should have its own evidence, reassessment point, and stop rule.

1. Verify the diagnosis pathway. Identify the clinician who evaluated ED, contributing factors, cardiovascular context, and established alternatives.
2. Specify the PRP. Record collection, device, disposable, spin, composition, volume, additives, injection sites, sessions, and operators.
3. Match the evidence. Compare the clinic protocol with trial population, comparator, endpoint, clinically important threshold, time point, harms, and attrition.
4. Correct the FDA claim. Separate any device clearance from the preparation, injection procedure, disease indication, and branded marketing name.
5. Define follow-up and cost. Obtain outcome measures, reassessment, stop criteria, adverse-event routing, privacy, itemized price, and refund terms.

The decisive question is: “What exact PRP preparation and ED injection protocol is being sold, which randomized evidence actually matches it, and who owns diagnosis, alternatives, adverse events, and follow-up?”